USSTOCK.TODAY
Regular Market
Log in Sign up

Ultragenyx shares plunge 44.7% premarket after GTX-102 Phase 3 failure

InvestorsHub +1 ·

RARE
RARE Ultragenyx Pharmaceutical Inc
$26.53 +2.79%
View chart & analysis →
  1. 1Ultragenyx (RARE) Angelman syndrome GTX-102 Phase 3 Aspire misses primary and key secondary endpoints
  2. 2Shares down 44.7% to $14.67 in premarket trading; no significant difference between treatment and placebo groups
  3. 3Evercore, Baird, JPMorgan among those cutting ratings and price targets; shares fall below 52-week low of $18.29

This 3-line summary is compiled from the report below.

InvestorsHub +1 View original ↗

Related 3-line summaries

Tesla Robotaxi Unsupervised Driving Less Than 0.2% of Waymo's CNN Business · 57m agoGlobal bond yields surge on concerns over government spending and prolonged high rates CNN Business · 57m agoAptevo Reports 93% Clinical Benefit Rate with Mipleta... Triple Combo in TP53-Mutant AML ACCESSWIRE +1 · 1h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news